Inhibrx Biosciences, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | -554.8% | -96.4% | -78.4% |
| FY2024 | 1,263.3% | 1,263.3% | 933.6% |
| FY2025 | -1,752.2% | -129.0% | -95.6% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | -554.8% | -96.4% | -78.4% |
| FY2024 | 1,263.3% | 1,263.3% | 933.6% |
| FY2025 | -1,752.2% | -129.0% | -95.6% |